Curis, Inc. (CRIS)
CRIS Stock Price Chart
Explore Curis, Inc. interactive price chart. Choose custom timeframes to analyze CRIS price movements and trends.
CRIS Company Profile
Discover essential business fundamentals and corporate details for Curis, Inc. (CRIS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Aug 2000
Employees
24.00
Website
https://www.curis.comCEO
James Dentzer
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
CRIS Financial Timeline
Browse a chronological timeline of Curis, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$8.25, while revenue estimate is $1.00m.
Stock split effective on 6 Jul 2026
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 May 2026
EPS came in at -$25.00 falling short of the estimated -$5.80 by -331.03%.
Earnings released on 19 Mar 2026
EPS came in at $24.60 surpassing the estimated -$11.80 by +308.47%, while revenue for the quarter reached $1.14m , missing expectations by -64.98%.
Earnings released on 13 Nov 2025
EPS came in at -$0.49 surpassing the estimated -$12.40 by +96.05%, while revenue for the quarter reached $3.18m , beating expectations by +11.05%.
Earnings released on 5 Aug 2025
EPS came in at -$0.68 surpassing the estimated -$39.80 by +98.29%, while revenue for the quarter reached $2.75m , beating expectations by +4.17%.
Earnings released on 6 May 2025
EPS came in at -$1.25 falling short of the estimated -$1.14 by -9.65%, while revenue for the quarter reached $2.38m , missing expectations by -10.23%.
Earnings released on 31 Mar 2025
EPS came in at -$25.20 surpassing the estimated -$27.20 by +7.35%, while revenue for the quarter reached $2.70m , beating expectations by +22.16%.
Earnings released on 14 Nov 2024
EPS came in at -$34.00 surpassing the estimated -$36.60 by +7.10%, while revenue for the quarter reached $2.93m , beating expectations by +29.26%.
Earnings released on 1 Aug 2024
EPS came in at -$2.03 falling short of the estimated -$1.79 by -13.20%, while revenue for the quarter reached $2.55m , beating expectations by +23.37%.
Earnings released on 7 May 2024
EPS came in at -$41.00 surpassing the estimated -$42.40 by +3.30%, while revenue for the quarter reached $2.09m , beating expectations by +4.24%.
Earnings released on 11 Mar 2024
EPS came in at -$40.60 surpassing the estimated -$42.20 by +3.79%, while revenue for the quarter reached $2.70m , missing expectations by -10.81%.
Earnings released on 2 Nov 2023
EPS came in at -$42.60 surpassing the estimated -$46.60 by +8.58%, while revenue for the quarter reached $2.83m , beating expectations by +11.54%.
Stock split effective on 29 Sept 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 3 Aug 2023
EPS came in at -$2.40 matching the estimated -$2.40, while revenue for the quarter reached $2.20m , missing expectations by -11.11%.
Earnings released on 4 May 2023
EPS came in at -$2.40 falling short of the estimated -$2.20 by -9.09%, while revenue for the quarter reached $2.30m , missing expectations by -7.36%.
Earnings released on 13 Mar 2023
EPS came in at -$2.40 surpassing the estimated -$2.80 by +14.29%, while revenue for the quarter reached $2.89m , missing expectations by -9.37%.
Earnings released on 9 Nov 2022
EPS came in at -$2.80 surpassing the estimated -$3.40 by +17.65%, while revenue for the quarter reached $2.83m , missing expectations by -7.28%.
Earnings released on 4 Aug 2022
EPS came in at -$3.40 matching the estimated -$3.40, while revenue for the quarter reached $2.39m , missing expectations by -8.58%.
Earnings released on 5 May 2022
EPS came in at -$3.60 surpassing the estimated -$64.00 by +94.38%, while revenue for the quarter reached $2.06m , missing expectations by -14.45%.
Earnings released on 24 Feb 2022
EPS came in at -$3.00 falling short of the estimated -$2.60 by -15.38%, while revenue for the quarter reached $3.14m , beating expectations by +5.92%.
Earnings released on 9 Nov 2021
EPS came in at -$2.40 surpassing the estimated -$2.60 by +7.69%, while revenue for the quarter reached $3.04m , beating expectations by +8.54%.
Earnings released on 3 Aug 2021
EPS came in at -$2.40 falling short of the estimated -$2.20 by -9.09%, while revenue for the quarter reached $2.29m , meeting expectations.
CRIS Stock Performance
Access detailed CRIS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
